CASE STUDY: EVOLUTION IN THE MEDICAL DEVICE SUPPLY CHAIN Cardinal Health and DHL discuss trust and partnership in logistics and back office
With
Steve Thompsett, CEO
DHL Supply Chain Australia and New Zealand
Michael Gardner,
(Former) VP Life Sciences & Healthcare
DHL Supply Chain Australia
Shane McCormack,
Senior Manager Supply Chain
Cardinal Health
Australian Health Journal segment
Filmed in Sydney | April 2025
Supply chain and logistics involve managing products globally, from manufacturing to distribution. This includes international shipping via air and sea, storing products in temperature-controlled warehouses, and delivering them to pharmacies, medical wholesalers, and hospitals within the domestic market.
Michael Gardner, (Former) VP Life Sciences & Healthcare, DHL Supply Chain Australia spoke to Australian Health Journal about the medical device industry being particularly complex; onboarding a new customer at DHL supply chain demands thorough preparation. This process involves understanding the customer’s operations and the lifecycle of their products, from their arrival at the warehouse to their use in patient care. Insight into the customer’s expectations is crucial to ensure seamless operations.
For Cardinal Health, a global manufacturer and distributor of medical products, the process begins when products arrive in Australia and are cleared by customs before being stored at their Sydney warehouse. From here, they fulfil orders for various clients, including hospitals and wholesalers, supported by DHL’s logistics services.
In this case study, Australian Health Journal was given the opportunity to talk to both the logistics provider and the end medical technology client in what is an evolving medical device supply chain.
Challenges in Australia include a limited manufacturing workforce and the distances to raw material sources, with all imported products being finished goods. Compliance with safety and regulatory standards is essential. In addition to logistics, DHL provides value-added services like equipment repairs and a 4PL service, which includes customer service support and accounts receivable, enhancing efficiency for Cardinal Health.
Credit: MedTech24 Conference, hosted by Medical Technology Association of Australia (MTAA) in Sydney, October 2024.
Source: Written by AUDIENCED, with use of generative AI on transcript
-
Understanding extracellular vesicles in cancer therapy research
Joy Wolfram is an Associate Professor at the Australian Institute for Bioengineering and Nanotechnology and the School of Chemical Engineering at the University of Queensland in Australia. Originally from Finland, she earned both her bachelor’s and master’s degrees in biology before transitioning to engineering with a PhD in nanotechnology completed in China. Wolfram has over a decade of experience working in hospitals in the United States before joining the University of Queensland.
Her research focuses on extracellular vesicles, which are crucial for cell communication both locally within tissues and over longer distances between organs. Her lab studies the roles of these vesicles in both health and disease, particularly in cancer. They investigate the harmful messages released by cancer cells that aid in tumour growth, specifically in breast cancer, while also exploring how to harness beneficial extracellular vesicles from healthy individuals as potential therapeutics.
-
Specialist emergency care clinics in rollout
Unlike Emergency Departments that operate within public hospitals and some private hospitals, a Walk-in Specialist Emergency Clinic is located in the community and designed to provide comprehensive, coordinated acute care – from initial consultation and diagnostic services, to treatment and specialist referral if required – without the patient having to visit a hospital.
Australian Health Journal spoke to the visionary, founder and CEO behind this WiSE Specialist Emergency clinic, Dr Pankaj Arora.
-
Investments to address health inequities in Prostate Cancer Care
Income, education, geographical location, and discrimination based on ethnicity, race, gender and sexual orientation, are only a fraction of factors that can negatively affect a person’s quality of cancer care. This is defined as the “equity gap” and it’s costing people their lives.
Timed to coincide with World Cancer Day 4th February 2025, Movember announced prostate cancer investment of $5.5 million. Eighteen grants (16 proposals and 2 community development grants) are slated to directly tackle inequities in prostate cancer care. The funding will be over three years with the grants spread across five countries – six in Canada, five in the United Kingdom, three in Australia, three in the United States and one in Ireland – each having a specific focus population and care area.
